Genevide, an incubation project of Cure Genetics, ...
2022.01.14
Genevide, an incubation project of Cure Genetics, ...
Recently, Genevide, an independent incubation company from Cure Genetics’s former molecular diagnostics business, announced the completion of a RMB 50 million angel round of financing led by Bioventure, co-invested by Qiming Ventures. Dr. Qiushi Li, former co-founder and COO of Cure Genetics, is named the co-founder and CEO of Genevide. “Genevide has built an Enzymes-mediated Duplex Exponential Amplification (EmDEATM) nPOCT technology platform with independent intellectual property portfolio using an innovative molecular enzyme cycle screening system based on enzyme characterization methods. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products. “ Dr. Qiushi Li, Co-Founder and CEO of Genevide said.

More

>
Cure Genetics Completed $60 Million Series B Finan...
2022.01.05
Cure Genetics Completed $60 Million Series B Finan...
On January 5, 2022, Cure Genetics Biotechnology Co., Ltd. (hereinafter referred to as "CureGenetics") announced the completion of a US$60 million Series B financing. This round of financing was led by strategic investor Advantech Capital, followed by Oriza Holdings, BOCG and Qiming Venture Partners, with China Renaissance acting as the exclusive financial advisor.

More

>
Boehringer Ingelheim and Cure Genetics Collaborate...
2021.01.18
Boehringer Ingelheim and Cure Genetics Collaborate...
Boehringer Ingelheim (BI) and Cure Genetics Co., Ltd (Cure Genetics) today announced a collaboration to develop novel adeno-associated viral (AAV) vectors for next-generation gene therapy through Cure Genetics's proprietary VELPTM platform. This new collaboration combines BI's experience in disease mechanism research and gene therapy development with Cure Genetics's expertise in viral library construction and high-efficient in vivo AAV screening, providing patients with potentially safer and more efficient novel AAV serotypes.

More

>
Cure Genetics Ranked among 2020 China’s Top 80 Hea...
2020.10.20
Cure Genetics Ranked among 2020 China’s Top 80 Hea...
On October 17, Cure Genetics was listed among the VentureBond 2020 China's Top 80 Healthcare Innovation Companies.

More

>
Cure Genetics’ two projects were selected for the ...
2019.12.13
Cure Genetics’ two projects were selected for the ...
Recently, the candidate projects for the 2019 Gusu Innovation and Entrepreneurship Leading Talents Program were announced, and two projects from Cure Genetics were selected, namely the development of novel adeno-associated viral vectors with tissue-specific targeting and the application of innovative AAV serotype for genetic disease treatment.

More

>